Get the Stockscreener App
13.91
1.68%
0.23
After Hours:
14.17
0.26
+1.87%
Oric Pharmaceuticals Inc stock is traded at $13.91, with a volume of 1.25M.
It is up +1.68% in the last 24 hours and up +29.04% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$13.68
Open:
$13.74
24h Volume:
1.25M
Relative Volume:
1.02
Market Cap:
$1.35B
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-7.3598
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
-3.47%
1M Performance:
+29.04%
6M Performance:
+182.72%
1Y Performance:
+49.09%
1-Day Range:
$13.42
$14.16
1-Week Range:
$13.24
$14.93
52-Week Range:
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.91 | 1.33B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
Analyzing drawdowns of ORIC Pharmaceuticals Inc. with statistical toolsVolume Spike & Proven Capital Preservation Methods - newser.com
What technical models suggest about ORIC Pharmaceuticals Inc.’s comebackVolume Spike & Reliable Price Action Trade Plans - newser.com
Will breakout in ORIC Pharmaceuticals Inc. lead to full recoveryQuarterly Portfolio Review & Low Volatility Stock Suggestions - newser.com
Oric Pharmaceuticals' (ORIC) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Historical volatility pattern of ORIC Pharmaceuticals Inc. visualized2025 Bull vs Bear & Growth Focused Entry Point Reports - newser.com
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko Sells 37,461 Shares - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $159,720.00 in Stock - MarketBeat
How robust is ORIC Pharmaceuticals Inc. (4TZ) stock financial position2025 Major Catalysts & High Accuracy Trade Alerts - newser.com
Oric Pharma CFO sells $159,718 in shares By Investing.com - Investing.com Canada
ORIC Pharmaceuticals Inc. stock trend forecast2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Visual analytics tools that track ORIC Pharmaceuticals Inc. performanceJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Candlestick signals on ORIC Pharmaceuticals Inc. stock today2025 Technical Overview & Safe Capital Growth Tips - newser.com
Insider Sell: Dominic Piscitelli Sells 11,000 Shares of ORIC Pha - GuruFocus
Oric Pharmaceuticals CEO Chacko Jacob sells $461k in stock By Investing.com - Investing.com Canada
Oric Pharmaceuticals stock hits 52-week high at 14.89 USD By Investing.com - Investing.com Nigeria
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighStill a Buy? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Trading Up 9.8%Here's What Happened - MarketBeat
What analysts say about ORIC Pharmaceuticals Inc stockGrowth Stock Opportunities & High Yield Trading Signals - earlytimes.in
How higher bond yields impact ORIC Pharmaceuticals Inc. (4TZ) stockJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Top chart patterns to watch in ORIC Pharmaceuticals Inc.Stop Loss & Fast Gaining Stock Strategy Reports - newser.com
Will ORIC Pharmaceuticals Inc. stock attract ESG investorsJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
Identifying reversal signals in ORIC Pharmaceuticals Inc.July 2025 Setups & AI Powered Market Entry Ideas - newser.com
How to use a screener to detect ORIC Pharmaceuticals Inc. breakouts2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-05 04:16:39 - newser.com
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate - Yahoo Finance
Published on: 2025-10-03 04:25:32 - newser.com
Is ORIC Pharmaceuticals Inc. stock poised for growth2025 Short Interest & Stepwise Trade Signal Guides - newser.com
Insider Selling: Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells 53,001 Shares of Stock - MarketBeat
Voya Investment Management LLC Reduces Position in Oric Pharmaceuticals, Inc. $ORIC - Defense World
ORIC Pharmaceuticals Inc 4TZ Stock Analysis and ForecastMarket Correction Analysis & Expert-Backed Recommendations That Deliver - earlytimes.in
Published on: 2025-09-29 09:52:14 - newser.com
ORIC Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & Learn the Secrets of Pro Traders - Early Times
Merus NV and ORIC Pharmaceuticals Inc at Citi BioPharma Conferen - GuruFocus
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Oct 06 '25 |
Sale |
14.52 |
11,000 |
159,719 |
48,317 |
| Chacko Jacob | PRESIDENT AND CEO |
Oct 06 '25 |
Sale |
12.32 |
37,461 |
461,520 |
531,419 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):